Clinical Trials Logo
  1. Home
  2. Healthy
  3. NCT01705249
  4. Details
NCT01705249 Clinical Trial

Bleeding Profile With Continuous Hormone Replacement Therapy of Activelle® in Postmenopausal Women

Healthy Clinical Trial

Official title:
Bleeding Profile With Continuous Hormone Replacement Therapy in Postmenopausal Women: A Prospective, Open, Multicenter Trial of Activelle® Treatment Following Switch From Trisekvens®

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01705249
Other study ID # KLIM-1408
Secondary ID
Status Completed
Phase Phase 4
First received October 8, 2012
Last updated February 27, 2017
Start date August 14, 2001
Est. completion date June 6, 2003

Study information
Verified date February 2017
Source Novo Nordisk A/S
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is conducted in Europe. The aim of this study is to investigate the bleeding profile after switch from Trisekvens® to Activelle® (1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)).

Recruitment information / eligibility
Status Completed
Enrollment 191
Est. completion date June 6, 2003
Est. primary completion date June 6, 2003
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 50 Years and older
Eligibility Inclusion Criteria:

- Healthy women

- At least 3 months on Trisekvens® before screening period

- Ability to understand and comply with the protocol requirements

Exclusion Criteria:

- Less than 12 months or more than 36 months postmenopausal judged by the Investigator

- Known, suspected, or past history of hormone dependent tumor/cancers

- Deep venous thrombosis, active thrombophlebitis, thromboembolic disorders, cerebrovascular accidents or past history of these conditions

- Ischemic heart disease or myocardial infarction within 6 months prior to randomization

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• 1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)
After a screening period of 12 weeks (three lunar months) in which the subjects still are on Trisekvens® followed by a treatment period of 24 weeks (six lunar months) in which the subjects are treated with Activelle®.

Locations
Country Name City State
Norway Novo Nordisk Investigational Site Kristiansand
Norway Novo Nordisk Investigational Site Kristiansund
Norway Novo Nordisk Investigational Site Larvik
Norway Novo Nordisk Investigational Site Oslo
Norway Novo Nordisk Investigational Site Trondheim
Sweden Novo Nordisk Investigational Site Borås
Sweden Novo Nordisk Investigational Site Göteborg
Sweden Novo Nordisk Investigational Site Göteborg
Sweden Novo Nordisk Investigational Site Kungsbacka
Sweden Novo Nordisk Investigational Site Linköping
Sweden Novo Nordisk Investigational Site Linköping
Sweden Novo Nordisk Investigational Site Linköping
Sweden Novo Nordisk Investigational Site Norrköping
Sweden Novo Nordisk Investigational Site Norrköping
Sweden Novo Nordisk Investigational Site Sigtuna
Sweden Novo Nordisk Investigational Site Södertälje
Sweden Novo Nordisk Investigational Site Stockholm
Sweden Novo Nordisk Investigational Site Stockholm
Sweden Novo Nordisk Investigational Site Uddevalla

Sponsors (1)
Lead Sponsor Collaborator
Novo Nordisk A/S

Countries where clinical trial is conducted

Norway,  Sweden, 

Outcome
Type Measure Description Time frame Safety issue
Primary Postmenopausal women's acceptance of bleeding After 24 weeks of treatment
Secondary Bleeding profile in postmenopausal women After 24 weeks of treatment
Secondary Acceptance of hot flushes and breast tenderness After 24 weeks of treatment
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1

External Links